A Canadian research team has registered a small trial to test whether tirzepatide, a GLP-1 medication currently used for weight loss and diabetes, could help people reduce cannabis use. The trial has not yet enrolled any patients, and it is still listed as not recruiting. But its existence signals that researchers are looking at GLP-1 medications for uses well beyond weight and metabolic health. If you or someone you know struggles with cannabis dependence, this is a development worth watching, even though it is very early.
If this trial eventually shows a benefit, it would not make tirzepatide available for cannabis dependence right away. Phase 3 trials take years to complete, and the results still need to be reviewed by regulators before any new use is approved. Even so, a positive result would give doctors and researchers a reason to study the drug further for addiction treatment, and it could open the door to formal approval down the road. The connection is not far-fetched. GLP-1 medications affect reward pathways in the brain, which is part of why researchers are curious whether they might reduce cravings for substances other than food. For now, this is a hypothesis being tested, not a treatment that is ready to use.
There is nothing for patients to act on yet, since the trial has not started and no one has been enrolled. I would suggest treating this as an early signal rather than a near-term option. If you are interested in how this develops, it is reasonable to check back on the trial's status periodically or ask your doctor whether they are aware of research into GLP-1 medications for addiction. In the meantime, existing, approved treatments for cannabis use disorder remain the appropriate path to discuss with a healthcare provider.
Key details
This trial could eventually make tirzepatide an option for cannabis dependence.
Read this on GLP1Laws: https://glp1laws.com/patient-lens/access-roundup-2026-06-30